About

Aims and scope

The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed, online journal of the Society for Immunotherapy of Cancer (SITC). The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance scientific understanding among the many stakeholders in this rapidly evolving field. Topics of interest range widely across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

Editorial Board

For information about JITC Editor-in-Chief Pedro Romero and his editorial team, please refer to the Editorial Board page.

Ownership

BMJ publishes JITC on behalf of the Society for Immunotherapy of Cancer.

Journal information

Publication Model Open access
Frequency Continuous
Launch date 2013
Digital Archive LOCKSS
Indexed by Web of Science Core Collection: Science Citation Index Expanded; MEDLINE, PubMed Central, Science Citation Index Expanded (SCIE), Scopus, DOAJ, Google Scholar
Impact Factor 9.913 (2019)
CiteScore 8.6 (2019)
Peer Review Model Single blind; the names of reviewers are hidden from the author
Print ISSN N/A
Online ISSN 2051-1426

Journal statistics (2018)

Acceptance Rate
Mean time from submission to first decision 44 days
Time from acceptance to online publication 21 days

Contact information

For all contact information please refer to the contact us page.

For Authors

Please refer to the Instructions for authors.

Subscriptions

To advertise

Rights and permissions

Affiliations

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Its mission is to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.

BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.

Equator

The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.

AllTrials logo

BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.